Drug Profile
HM 15136
Alternative Names: LAPSGlucagon Analog; HM-15136Latest Information Update: 09 Aug 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihypoglycaemics; Obesity therapies; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Congenital hyperinsulinism
- Preclinical Obesity
Most Recent Events
- 15 Jun 2023 Pharmacodynamics data from a preclinical trial in Hyperinsulinaemia presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
- 11 Nov 2022 pharmacodynamic data of HM 15136 in obesity presented at 58th Annual Meeting of the European Association for the Study of Diabetes (EASD-2022)
- 17 Jun 2022 Hanmi Pharmaceutical receives Rare paediatric disease designation from the US FDA in Congenital-hyperinsulinism before June 2022 (Hanmi Pharmaceutical pipeline, June 2022)